Forensic Accounting Intelligence

Red Flags

Who Is The Next Enron?

Issue #6 · April 17, 2026 · Beneish M-Score • Altman Z-Score • Accruals Analysis • Governance Signals

⚠ Important Disclaimer: This newsletter applies academic forensic accounting models (Beneish M-Score, Altman Z-Score, Cash/Earnings Divergence Analysis, Governance Signals) to publicly available financial data. The presence of red flags is not evidence of fraud, wrongdoing, or impending financial distress. These are quantitative screens that identify statistical patterns warranting further due diligence. Many legitimate companies — particularly high-growth companies — exhibit elevated M-Scores or Z-Scores for entirely explainable, non-fraudulent reasons. This newsletter is for educational and research purposes only and does not constitute investment advice, a recommendation to sell or short any security, or an allegation of wrongdoing. Always consult a qualified financial advisor before making investment decisions. Past accuracy of these models does not guarantee future results.

Forensic Scoring Methodology — 100 Points Total ▼ click to expand

Four academic models combined into a composite fraud-risk score, using the same financial data already crawled by the persistent pipeline — no additional data collection. This panel appears only once per browser session.

Beneish M-Score (35 pts) — 1999 academic model detecting earnings manipulation via 8 financial ratios. The M-Score is a negative scale: values closer to zero are MORE suspicious. For example, −1.12 is closer to zero than −1.78, so −1.12 is the riskier score. Any score closer to zero than −1.78 classifies as a statistically likely manipulator. The model flagged Enron at this level in FY1997–1998, three years before the 2001 collapse.
M > −1.78 → 35 pts | M > −2.22 → 18 pts (grey zone)

Cash vs Earnings Divergence (25 pts) — Accruals ratio = (Net Income − Operating Cash Flow) / Total Assets. In every major accounting fraud, earnings were positive while cash flows lagged severely. "You can fake earnings, not cash." Multi-year pattern analysis (years with NI>0 but OCF<0) is the Luckin Coffee / Wirecard signature.
Accruals > 0.10 + NI>0/OCF<0 pattern → 25 pts

Altman Z-Score (20 pts) — 1968 bankruptcy prediction model. Five-factor formula incorporating working capital, retained earnings, EBIT, market cap vs debt, and revenue efficiency. Fraudulent accounting and financial collapse are often correlated.
Z < 1.81 → 20 pts (distress) | Z < 2.99 → 10 pts (grey zone)

Governance Signals (20 pts) — Short interest >20% of float (market-level fraud suspicion), minimal insider ownership, goodwill >40% of assets (acquisition risk / hidden write-offs), extreme beta.
Short >20% → up to 6 pts | Goodwill >40% → 5 pts | Low insider ownership → up to 4 pts

⚠ High-Growth False Positives: Fast-growing companies (high SGI, rising DSRI, negative OCF) will naturally score high on these models without any fraud. Look for the HIGH-GROWTH CAUTION notes above each stock's triggered flags. Universe: Russell 1000 (≥$1B market cap), screened weekly. Top 3 highest-scoring stocks featured. 6-month exclusion window prevents repeat coverage.

This Issue

SRPT — Sarepta Therapeutics, Inc. (HIGH, 60/100)
APLS — Apellis Pharmaceuticals, Inc. (HIGH, 59/100)

#1 Highest Risk — Healthcare

SRPT — Sarepta Therapeutics, Inc.

HIGH Red Flags Score: 59.9 / 100

$18.59

Market Cap: $1.9B

Biotechnology

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients

📌 5-Year Weekly HLOC Chart: Weekly candlesticks showing High, Low, Open, Close. Green candles = weekly close above open; red = close below open. Use this to contextualise the long-term price trend over the period covered by the forensic analysis below.

📌 Revenue / Net Income / Operating Cash Flow: Quarterly where available, otherwise annual. Blue = Revenue. Green = Net Income. Sand = Operating Cash Flow. Bars extend below zero when negative. A persistent gap between net income and operating cash flow is the core accruals signal.

📌 Revenue vs Receivables: If accounts receivable grow faster than revenue, the company is booking sales before the cash arrives — the classic channel-stuffing or early-recognition pattern. Enron's AR grew 240% in the two years before collapse while revenue grew only 40%.

📌 Earnings vs Cash Flow: Shaded red columns indicate years where net income was positive but operating cash flow was negative — the Luckin Coffee and Wirecard signature. "You can fake earnings, not cash." A persistent gap (accruals) is the #1 quantitative fraud predictor.

📌 AR/Revenue Ratio (DSRI Trend): A rising ratio means receivables are accumulating faster than sales — a key Beneish Days Sales Receivable Index (DSRI) signal. Values consistently above 0.15–0.20 for most sectors warrant scrutiny. The Beneish model flags companies where DSRI exceeds 1.46× the prior year.

📌 Accruals Ratio (TATA) by Year: Total Accruals to Total Assets = (Net Income − Operating Cash Flow) / Total Assets. Red bars (>0.05) indicate earnings quality concern; bars above 0.10 are a strong fraud signal. Negative TATA (green) is healthy — cash flow exceeds reported earnings.

📌 Gross Margin Trend (GMI): Sustained margin compression creates pressure to manipulate reported earnings to meet analyst expectations. The Beneish Gross Margin Index (GMI) flags when prior-year margins were significantly better than the current year. Red bars = margin declined; green = improved.

📌 Altman Z-Score: Five-factor bankruptcy prediction model. Red zone (<1.81) has historically produced significant failure rates. Companies in financial distress have strong incentives to manipulate accounting — distress and fraud are correlated. Grey zone (1.81–2.99) warrants monitoring.

📌 Score Decomposition: The composite Red Flags Score (0–100) broken down by contributing model. Beneish M-Score contributes up to 35 pts, Cash Divergence 25 pts, Altman Z-Score 20 pts, Governance Signals 20 pts. Scores ≥65 = CRITICAL, ≥45 = HIGH, ≥25 = ELEVATED.

Forensic Analysis

### 1. THE CORE CONCERN

Sarepta Therapeutics' Beneish M-Score of -1.32 breaches the -1.78 manipulation threshold on a negative scale where values closer to zero indicate higher risk of earnings manipulation. This places it in the manipulator zone, consistent with statistical patterns of firms distorting financials. Reinforcing this, the Altman Z-Score of 0.80 falls deep in the distress zone (<1.81), signaling elevated bankruptcy risk, while TATA at 0.111 shows accruals comprising 11.1% of assets, raising earnings quality questions. Sales Growth Index (SGI) at 1.53 reflects 53% year-over-year revenue growth, and short interest at 24.6% of float indicates substantial market skepticism. The overall Red Flags Score of 59.9/100 is high. Notably, revenue has grown consistently from $0.7B to $0.9B to $1.2B to $1.9B (3-year CAGR of 39.4%), a dynamic that can trigger such forensic signals without implying fraud.

### 2. HISTORICAL PRECEDENT

This pattern echoes Enron Corporation in fiscal years 1997–1998, where the Beneish M-Score similarly breached -1.78 (closer to zero than Sarepta's -1.32), flagging manipulation three years before its 2001 collapse. Enron exhibited rapid reported growth amid deteriorating cash flows and high accruals, with an Altman Z-Score trending toward distress. Like Sarepta, Enron operated in a high-growth sector (energy trading), where aggressive revenue recognition masked underlying weaknesses until special purpose entities unraveled. Sarepta's biotech context shares parallels in R&D-intensive growth, but the M-Score alignment warrants scrutiny of revenue sustainability.

### 3. WHAT TO VERIFY

- **Revenue composition and recognition**: Examine 10-K/10-Q footnotes for breakdowns of net product sales versus milestone/collaboration revenue; quantify deferred revenue changes and channel inventory levels to assess potential stuffing, given SGI of 1.53.

- **Accruals drivers**: Review cash flow statement reconciliations and MD&A for sources of the 11.1% TATA; specifically, identify non-cash adjustments in operating income and verify if they tie to legitimate R&D capitalization or one-time items rather than core earnings inflation.

- **Cash conversion post-growth**: Cross-check operating cash flow trends against capex/R&D spend in the 10-Q; confirm if negative OCF (flagged in high-growth caution) funds verifiable clinical trials, manufacturing scale-up, or sales force expansion, with details on customer concentration and payment terms.

### 4. COUNTERARGUMENTS

High-growth biotech firms like Sarepta routinely trigger forensic flags due to legitimate dynamics, not manipulation. The 39.4% revenue CAGR—from $0.7B to $1.9B over three years—directly explains SGI (1.53), as rapid commercialization of therapies (e.g., gene therapies for rare diseases) inflates ratios like DSRI and produces temporary negative OCF from upfront R&D and sales investments. Accruals ratio at 0.000 is negligible (>0.05 concerning), with zero years of positive net income over negative OCF and $0.0B 5-year NI-OCF divergence, indicating no systematic earnings-cash disconnect. Altman distress may stem from biotech volatility (debt for trials), not insolvency, and short interest (24.6%) could reflect binary clinical risks rather than accounting fraud. In sum, signals likely reflect growth execution in a capital-intensive sector, where cash burn precedes profitability.

(Word count:

Triggered Forensic Flags

⚠️⚠️ HIGH-GROWTH CAUTION: Revenue CAGR 39%/yr over the measured period. Many forensic signals (high SGI, rising DSRI, negative OCF) are EXPECTED in high-growth companies and do NOT necessarily indicate fraud. Verify that cash burn is funding genuine growth (R&D, sales expansion, customer acquisition) rather than masking accounting manipulation.

❌Beneish M-Score -1.32 — breaches the −1.78 manipulation threshold. The M-Score is a negative scale where values closer to zero are MORE suspicious (e.g. −1.12 is closer to zero than −1.78, therefore riskier). Scores closer to zero than −1.78 classify as statistically likely earnings manipulators — the same model flagged Enron at this level in FY1997–1998, three years before the 2001 collapse. [35/35 pts]

❌TATA 0.111 — accruals represent 11.1% of total assets (earnings quality concern)

❌SGI 1.53 — revenue grew 53% year-on-year (rapid growth can mask channel stuffing)

❌Altman Z-Score 0.80 in DISTRESS ZONE (<1.81) — statistically high probability of financial distress. Companies scoring <1.81 have historically failed at significantly elevated rates.

❌Short interest 24.6% of float — elevated market scepticism (threshold: 20%)

Key Metrics

Beneish M-Score -1.32 ❌	Altman Z-Score 0.80 ❌	Accruals Ratio 0.000 ✅	Short Interest 24.6%
Beneish Score 35/35 pts	Altman Score 20/20 pts	Cash Div Score 0/25 pts	Gov Score 5/20 pts

Ticker $SRPT is available to trade on eToro, where it may be available for Puts or a Short position.

#2 Highest Risk — Healthcare

APLS — Apellis Pharmaceuticals, Inc.

HIGH Red Flags Score: 59.4 / 100

$22.80

Market Cap: $2.9B

Biotechnology

About Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedi

Forensic Analysis

### 1. THE CORE CONCERN

The most prominent quantitative signal in Apellis Pharmaceuticals' (APLS) financials is its Beneish M-Score of 18.06, which breaches the -1.78 manipulation threshold on a scale where values closer to zero are more suspicious. This places APLS in a category statistically associated with earnings manipulation, as the model assigns full points (35/35) for this metric. Compounding this, the Altman Z-Score stands at 0.00, firmly in the distress zone below 1.81, indicating elevated bankruptcy risk based on historical patterns. Short interest at 22.1% of float further reflects market skepticism exceeding the 20% threshold. While revenue has grown consistently from $0.1B to $0.8B over four years (3-year CAGR of 127.3%), these forensic ratios—particularly the M-Score—raise questions about whether reported results fully align with underlying economics, warranting closer scrutiny amid a $2.9B market cap.

### 2. HISTORICAL PRECEDENT

This pattern echoes Enron Corporation in fiscal years 1997–1998, where the Beneish M-Score similarly breached the -1.78 threshold (reaching levels closer to zero than the cutoff, signaling high manipulation risk). Enron exhibited rapid reported growth alongside forensic red flags like elevated sales growth index (SGI) components, which masked off-balance-sheet manipulations and aggressive revenue recognition. Three years later, in 2001, Enron collapsed amid revelations of structured finance vehicles inflating earnings. APLS shares biotech-sector parallels in high-growth reporting but mirrors Enron's M-Score distress and sales growth index of 1.97 (97% YoY revenue increase), potentially indicating similar pressures to present accelerating trajectories.

### 3. WHAT TO VERIFY

Investigators should prioritize these three questions, sourcing answers from recent 10-K/10-Q filings or management commentary:

- How does the company reconcile the Beneish M-Score components, particularly SGI (1.97) and any depreciation or receivables trends, with detailed breakdowns of revenue recognition policies for its lead product (e.g., Empaveli/Syfovre) under ASC 606, including deferred revenue movements and contract acquisition costs capitalized?

- What is the cash conversion cycle trajectory, and can management provide segment-level validation (e.g., via customer concentration data or inventory turns) that 97% YoY revenue growth stems from unit sales expansion rather than extended payment terms or channel loading?

- With an Altman Z-Score of 0.00, what is the projected cash runway based on current burn rates, and how do liquidity covenants or debt facilities (if any) factor into working capital management disclosures?

### 4. COUNTERARGUMENTS

Several innocent explanations align with APLS's profile as a pre-profitability biotechnology firm in a high-growth phase. Revenue has expanded consistently ($0.1B → $0.1B → $0.4B → $0.8B), delivering a 127.3% 3-year CAGR—legitimately triggering flags like high SGI (1.97), negative operating cash flow, and M-Score components, as these are commonplace in scaling biotechs funding R&D, clinical trials, and sales ramps rather than fraud. The accruals ratio of 0.000 remains well below concerning levels (>0.05), with zero years of positive net income paired to negative OCF and $0.0B 5-year NI-OCF divergence, suggesting no systematic earnings-cash disconnect. Altman Z-Score unreliability in loss-making growth companies (Red Flags Score 59.

Triggered Forensic Flags

⚠️⚠️ HIGH-GROWTH CAUTION: Revenue CAGR 127%/yr over the measured period. Many forensic signals (high SGI, rising DSRI, negative OCF) are EXPECTED in high-growth companies and do NOT necessarily indicate fraud. Verify that cash burn is funding genuine growth (R&D, sales expansion, customer acquisition) rather than masking accounting manipulation.

⚠️⚠️ PRE-PROFITABILITY CONTEXT: Company is currently loss-making. Pre-profitability companies often show negative OCF and high accruals simply due to investment phase economics. Altman Z-Score and accruals models are less reliable for companies not yet generating sustainable earnings. Focus on cash runway and revenue growth quality instead.

❌Beneish M-Score 18.06 — breaches the −1.78 manipulation threshold. The M-Score is a negative scale where values closer to zero are MORE suspicious (e.g. −1.12 is closer to zero than −1.78, therefore riskier). Scores closer to zero than −1.78 classify as statistically likely earnings manipulators — the same model flagged Enron at this level in FY1997–1998, three years before the 2001 collapse. [35/35 pts]

❌SGI 1.97 — revenue grew 97% year-on-year (rapid growth can mask channel stuffing)

❌Altman Z-Score 0.00 in DISTRESS ZONE (<1.81) — statistically high probability of financial distress. Companies scoring <1.81 have historically failed at significantly elevated rates.

❌Short interest 22.1% of float — elevated market scepticism (threshold: 20%)

Key Metrics

Beneish M-Score 18.06 ❌	Altman Z-Score 0.00 ❌	Accruals Ratio 0.000 ✅	Short Interest 22.1%
Beneish Score 35/35 pts	Altman Score 20/20 pts	Cash Div Score 0/25 pts	Gov Score 4/20 pts

Ticker $APLS is available to trade on eToro, where it may be available for Puts or a Short position.

Red Flags by RoboMacro — Forensic Accounting Intelligence | Issue #6 | April 17, 2026

Models: Beneish (1999), Altman (1968). Data: Yahoo Finance, SEC EDGAR, Financial Modeling Prep.

This publication is for educational purposes only. Not investment advice. Presence of red flags does not constitute an allegation of fraud or wrongdoing. Do your own due diligence.

Cartographic Modernism